Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236054 · ClinicalTrials.gov registry record · Phase 3
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
A Phase 3 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT00236054 is a Phase 3 study that has completed, run by Cephalon. The registered enrollment target is 440 participants.
The verdict
NCT00236054, a Phase 3 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD)
Interventions
- DRUG Gabitril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00236054
The ClinicalTrials.gov registry entry for NCT00236054 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gabitril is the first listed.
NCT00236054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00236054 about?
NCT00236054 is a clinical study titled "A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder". The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD)
What is the current status of trial NCT00236054?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2004-10. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00236054?
The interventions under investigation include: Gabitril (DRUG).
Who is sponsoring clinical trial NCT00236054?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.